# Pharmaceutical Executive - Leadership, Strategy & Market Access > Markdown mirror of DialtoneApp's public top-site detail page for `pharmexec.com`. URL: https://dialtoneapp.com/top-sites/pharmexec.com/index.md Canonical HTML: https://dialtoneapp.com/top-sites/pharmexec.com ## Summary - Domain: `pharmexec.com` - Website: https://pharmexec.com - Description: ai readable | score 20 | purchase read only - Label: ai_readable - Payment surface: Not available - Purchase boundary: read_only - Control boundary: unknown - Rank: 186145 ## robots ~~~text User-agent: * Disallow: /search Disallow: /preview/ Disallow: /*[*]*$ Sitemap: https://www.pharmexec.com/sitemap.xml Sitemap: https://www.pharmexec.com/sitemap-news.xml ~~~ ## llms ~~~text # PharmExec > PharmExec - Healthcare Publication - Base URL: https://www.pharmexec.com - Generated: 2026-04-25T05:27:26.363Z - Content updates: multiple times daily ## Content Access for AI Agents This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML. **Supported content types:** - `text/markdown` — Clean Markdown with YAML frontmatter - `text/plain` — Plain text (same as Markdown) - `text/html` — Default HTML response **Example request:** ``` curl -H "Accept: text/markdown" https://www.pharmexec.com/view/article-slug ``` **YAML frontmatter schema** (returned with every Markdown response): | Field | Type | Description | |-------|------|-------------| | `title` | string | Article headline | | `description` | string | Summary/excerpt (max 300 chars) | | `url` | string | Canonical article URL | | `canonical_url` | string | Canonical URL if different from `url` | | `published` | ISO 8601 | Original publication date | | `modified` | ISO 8601 | Last modification date | | `authors` | string[] | Author display names | | `content_type` | string | Content category (e.g., "News", "Clinical") | | `categories` | string[] | Taxonomy categories | | `tags` | string[] | SEO tags | | `image` | string | Featured image URL | | `publisher` | string | Publication/site name | **Discovery headers** (included on all responses): - `Link: ; rel="llms"` — RFC 8288 link to this file - `X-Llms-Txt: https://www.pharmexec.com/llms.txt` — Explicit discovery header ## Usage Policy - Robots policy: [https://www.pharmexec.com/robots.txt](https://www.pharmexec.com/robots.txt) - Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329) - Rate guidance: prefer RSS and sitemap feeds over crawling individual pages - Attribution: All content © MJH Life Sciences. Include source URLs when citing. ## Content Categories - [Content Engagement Hubs](https://www.pharmexec.com/content-engagement-hubs) - [Country Reports](https://www.pharmexec.com//topic/country-reports) - [Editorial Podcasts](https://www.pharmexec.com/editorial-podcasts) - [Editorial Videos](https://www.pharmexec.com/editorial-videos) - [Events](https://www.pharmexec.com/events) - [Front & Center](https://www.pharmexec.com/front-center) - [News](https://www.pharmexec.com/news) - [Pharma Pulse](https://www.pharmexec.com/pharma-pulse) - [Profiles in Medicine](https://www.pharmexec.com/profiles-in-medicine) - [Sponsored Content](https://www.pharmexec.com/sponsored-content) - [Sponsored Podcasts](https://www.pharmexec.com/sponsored-podcasts) - [Sponsored Videos](https://www.pharmexec.com/sponsored-videos) - [Topic](https://www.pharmexec.com/topic) - [Video Series](https://www.pharmexec.com/video-series) - [Webcasts](https://www.pharmexec.com/webcasts) - [Whitepapers](https://www.pharmexec.com/whitepapers) ## Featured Content - [FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression](https://www.pharmexec.com/view/fda-priority-voucher-compass-psychedelic-treatment-resistant-depression): FDA granted Compass Pathways with a rolling review for COMP360, a proprietary formulation of synthetic psilocybin, in treatment-resistant depression. - [Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie](https://www.pharmexec.com/view/daily-fda-issues-crl-abbvie): In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to... - [FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application ](https://www.pharmexec.com/view/fda-issues-crl-abbvie-trenibotulinumtoxine-biologics-license-application): FDA issues Complete Response Letter to AbbVie’s trenibotulinumtoxinE, delaying a potential first-in-class aesthetic neurotoxin over manufacturing ques... - [Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free](https://www.pharmexec.com/view/regeneron-agrees-lower-drug-costs-us-patients-provide-otarmeni-free): Regeneron announces agreement with the U.S. Government to set drug prices similarly to foreign prices, along with providing a new gene therapy free to... - [The Long Wait for Rare Disease Treatment Approval: Q&A with Dr. Patricia E. Greenstein](https://www.pharmexec.com/view/long-wait-rare-disease-treatment-approval-patricia-greenstein): Traditional randomized trials are often impractical for treatments in the rare and ultra rare disease space. - [Lessons Learned in the Current Biotech Funding Environment](https://www.pharmexec.com/view/lessons-learned-current-biotech-funding-environment): Maher Masoud, CEO of MaxCyte, explains how the current environment is impacting the entrepreneurial spirit in the pharmaceutical industry. - [The Ron Lanton Report: Where Innovations Happen](https://www.pharmexec.com/view/ron-lanton-report-where-innovations-happen): In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructu... - [FDA Approves Otarmeni Gene Therapy for OTOF-Related Hearing Loss](https://www.pharmexec.com/view/fda-otarmeni-gene-therapy-otof-related-hearing-loss): Early clinical data from the CHORD trial supported accelerated approval of the first gene therapy targeting OTOF-related hearing loss under the FDA Co... - [Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent](https://www.pharmexec.com/view/daily-fda-expands-approvals-tzield-and-dupixent): In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent... - [FDA Approves Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children](https://www.pharmexec.com/view/fda-approves-tzield-delay-onset-stage-3-type-1-diabetes-young-children): FDA expands its approval of Tzield to children as young as one with stage 2 type 1 diabetes, extending the first disease-modifying therapy into an ear... ## Feeds and Indexes - [RSS Feed](https://www.pharmexec.com/rss.xml): Latest articles in XML syndication format - [Sitemap](https://www.pharmexec.com/sitemap.xml): Complete URL index for all published pages - [News Sitemap](https://www.pharmexec.com/sitemap-news.xml): Recent articles optimized for news indexing - [Authors Directory](https://www.pharmexec.com/authors): Browse all contributors and their published work ~~~ ## llms-full Not found.